ClinicalTrials.gg
RecruitingNCT07120048INDICATEUpdated Oct 2, 2026

Real World Data Collection on the INSPIRIS RESILIA Aortic Valve

An observational study in Aortic Valve Disease, sponsored by Edwards Lifesciences. Recruiting at 15 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Edwards Lifesciences · Observational

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.
Updated Oct 2, 20261 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 16 studies in Aortic Valve Disease by Edwards Lifesciences — 3 open to participants now, 4 under way, none of them phase 3. Aortic Valve Disease · Edwards Lifesciences.

Started
2025
the only one that year
Observational
5 of 16
2 open now
Registered
15th of 16
by date

Among the 16 studies in Aortic Valve Disease by Edwards Lifesciences, this one is the only one that started in 2025, is one of 5 observational ones, and was the 15th registered.

Aortic Valve Disease

235 studies on the registry are indexed under Aortic Valve Disease; 71 are open to participants now.

Browse Aortic Valve Disease studies →

Open to participants now

3 of the 16 studies in Aortic Valve Disease by Edwards Lifesciences are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 46 Aortic Valve Disease studies recruiting now, 34 (74%) set no upper age limit and 5 (11%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Aortic Valve Disease by Edwards Lifesciences, or all of them as a file.
02

Study summary

Collect real-world data on hemodynamic and clinical outcomes of the INSPIRIS RESILIA Aortic Valve, Model 11500A, in subjects requiring replacement of their native or prosthetic aortic valve as the only heart valve procedure during the index procedure, with or without other concomitant procedures.

Read the detailed description

Subjects in the INDICATE registry study will be enrolled at up to 20 sites in Germany. Up to 500 subjects will be implanted with the INSPIRIS RESILIA Aortic Valve in this registry.

03

Conditions studied

  • Aortic Valve Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects from Germany who meet all the study inclusion criteria and none of the study exclusion criteria who undergo an aortic valve replacement with the Model 11500A heart valve and voluntary sign a consent form to agree to participate in the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients requiring an aortic valve replacement using the INSPIRIS RESILIA aortic valve according to its intended purpose
  2. Patients with standard-of-care pre-procedure imaging evaluation (echocardiography and CT) data available
  3. Age ≥ 18 years
  4. Provision of written

Exclusion criteria

Exclusion Criteria:

  1. Active endocarditis/myocarditis or endocarditis/myocarditis within 3 months prior to the scheduled aortic valve replacement surgery
  2. Emergency procedure
  3. Patients requiring a non-aortic heart valve procedure during the index procedure
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Target follow-up
3 Months
Patient registry
Yes

Groups and cohorts

  • Edwards INSPIRIS RESILIA Aortic Valve

    Subjects who were treated with the INSPIRIS RESILIA Aortic Valve

    Device: Edwards INSPIRIS RESILIA Aortic Valve

Interventions

  • DeviceEdwards INSPIRIS RESILIA Aortic Valve

    Surgical replacement of the aortic valve with the Edwards INSPIRIS RESILIA Aortic Valve

06

What researchers measure

Primary outcomes

  1. Subject's average mean gradient measurement over time

    Mean gradient is the average flow of blood through the aortic valve measured in millimeters of mercury. Gradients are evaluated by echocardiography over time. In general, a higher value is considered worse, and a lower value is considered better but the value is dependent on the size and type of valve.

    Time frame: Prior to discharge (an average of 7 to 10 days after surgery) and at 3 months

  2. Subject's average peak gradient measurement over time

    Peak gradient is the maximum value measured of flow of blood through the aortic valve as measured in millimeters of mercury. Gradients are evaluated by echocardiography over time. In general, a higher valve is considered worse, and a lower value is considered better, but the value is dependent on the size and type of valve.

    Time frame: Prior to discharge (an average of 7 to 10 days after surgery) and at 3 months

  3. Amount of aortic transvalvular regurgitation in subjects over time

    Valvular regurgitation occurs when the valve in the heart does not close tightly allowing some of the blood that was pumped out of the heart to leak back into it. Valvular regurgitation is evaluated by echocardiography over time. It is assessed by four categories, which are "no/trace leak", "a mild leak", "a moderate leak", and "a severe leak". A severe leak indicates a worsening outcome.

    Time frame: Prior to discharge (an average of 7 to 10 days after surgery) and at 3 months

  4. Amount of aortic paravalvular regurgitation in subjects over time

    Paravalvular leak refers to blood flowing through a channel between the implanted artificial valve and the cardiac tissue as a result of inappropriate sealing. Paravalvular leak is evaluated by echocardiography over time. It is assessed by four categories, which are "no/trace leak", "a mild leak", "a moderate leak", and "a severe leak". A severe leak indicates a worsening outcome.

    Time frame: Prior to discharge (an average of 7 to 10 days after surgery) and at 3 months

Secondary outcomes

  1. Subject's New York Heart Association (NYHA) functional classification at 3 months as compared to baseline.

    The New York Heart Association (NYHA) functional classification system relates symptoms to everyday activities and the patient's quality of life. Class I. No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea (shortness of breath). Class II. Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea (shortness of breath). Class III. Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or dyspnea. Class IV. Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases.

    Time frame: Baseline and 3 months

07

Study locations

15 of 15 sites recruiting
  • Universitätsklinikum Heidelberg
    Heidelberg, Baden-Wurttemberg, Germany
    Recruiting
    • Rawa Arif, Prof. Dr. med. · Principal investigator
  • Rhön Klinikum Campus Bad Neustadt
    Bad Neustadt an der Saale, Bavaria, Germany
    Recruiting
    • Anno Diegeler, Prof. Dr. med. · Principal investigator
  • Universitätsklinikum Erlangen
    Erlangen, Bavaria, Germany
    Recruiting
    • Friedrich Mellert, PD Dr. med. · Principal investigator
  • LMU Klinikum München
    Munich, Bavaria, Germany
    Recruiting
    • Sven Peterss, Prof. Dr. · Principal investigator
  • TUM Klinikum Deutsches Herzzentrum
    Munich, Bavaria, Germany
    Recruiting
    • Stephanie Voss, PD Dr. med · Principal investigator
  • Klinikum Passau
    Passau, Bavaria, Germany
    Recruiting
    • Robert Balan, Dr. med. · Principal investigator
  • Klinikum Oldenburg
    Oldenburg, Lower Saxony, Germany
    Recruiting
    • Andreas Martens, Prof. Dr. med. · Principal investigator
  • Herz- und Diabeteszentrum NRW
    Bad Oeynhausen, North Rhine-Westphalia, Germany
    Recruiting
    • René Schramm, Prof. Dr. med · Principal investigator
  • Universitätsklinikum Bonn
    Bonn, North Rhine-Westphalia 53127, Germany
    Recruiting
    • Farhad Bakhtiary, Prof. Dr. med. · Principal investigator
  • Helios Universitätsklinikum Wuppertal
    Wuppertal, North Rhine-Westphalia, Germany
    Recruiting
    • Lisa Müller, Dr. med. · Principal investigator
  • Herzzentrum Dresden
    Dresden, Saxony, Germany
    Recruiting
    • Klaus Matschke, Prof. Dr. med. · Principal investigator
  • Herzzentrum Leipzig
    Leipzig, Saxony, Germany
    Recruiting
    • Michael Borger, Prof MD · Principal investigator
  • UKSH Universitätsklinikum Schleswig-Holstein, Campus Kiel
    Kiel, Schleswig-Holstein, Germany
    Recruiting
    • Gregor Warnecke, Prof. Dr. med. · Principal investigator
  • Universitätsklinikum Jena
    Jena, Thuringia, Germany
    Recruiting
    • Torsten Doenst, Prof. Dr. med. · Principal investigator
  • Deutsches Herzzentrum der Charité Berlin
    Berlin, Germany
    Recruiting
    • Jörg Kempfert, Prof. Dr. med. · Principal investigator
08

References and documents

Individual participant data

Plan to share: No — There is no plan to share individual participant data (IPD) with other researchers.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2026, 17 months after the start.

Of 56 observational studies under Aortic Valve Disease, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 97. This study's planned 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2025
First posted
Aug 13, 2025
StartActual
Jul 30, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Universitätsklinikum Bonn · Bonn, Germany
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    1 site added
    Show site
    • Universitätsklinikum Bonn · Bonn, Germany
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07120048
Responsible party
Sponsor
First posted
Aug 13, 2025
Start date
Jul 30, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Oct 2, 2026

Study contacts

Sabrina Hundt, PhD
Contact
sabrina_hundt@edwards.com
+49 151 67550601
Torsten Doenst, Prof. Dr. med.
principal investigator · Jena University Hospital, University of Jena

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion